Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (7771)	11/19/1998 8:01:00 PM
From: Robert S.	Read Replies (2) \| Respond to of 17367

RobertK, thanks for the information from the abstract you posted. If we accept that BPI neutralizes cytokines, how then does this address other immune system components such as eicosanoids, complement components, and/or kinins? To complicate matters, it appears that cytokines play both pathogenic and protective roles; hence, the dilemma in combating such a complex disease. Message 6356208

To: Robert K. who wrote (7771)	11/29/1998 7:36:00 PM
From: Robert S.	Read Replies (1) \| Respond to of 17367

RobertK, I was mistaken in stating that BPI did not have an effect upon cytokines; if this is beneficial to a patient, however, remains a matter of controversy. Since cytokines play both pathogenic and protective roles, inhibiting the inflammatory response may not be the best therapeutic course of action. And what of the other mediators and components? Undetected L-forms? Finally, the heterogeneous nature and timing of mediator release and balance, when coupled with the factors above, illustrates why successfully combating a complex, multifactorial malady (e.g., sepsis) is so extraordinarily difficult. Message 6356208